UCB has received a not-approvable letter from the U.S. FDA for lacosamide for the treatment of diabetic neuropathic pain in adults.
Filed under: Sodium channel | Tagged: na channel, Regulatory, Sodium channel, UCB | Leave a Comment »
UCB receives non approvable letter for lacosamide in diabetic neuropathic pain
Posted on July 30, 2008 by crimsoncanary
EMEA issue positive opinion for UCBs lacosamide for the treatment of epilepsy
Posted on June 26, 2008 by crimsoncanary
UCB have announced that the EMEA has issued a positive opinion or lacosamide (Vimpat) for the adjunctive treatmentof partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older
Filed under: Sodium channel | Tagged: harkoseride, lacosamide, na channel, Sodium channel, UCB, Vimpat, voltage gated | Leave a Comment »
UCB announce Phase IIa data on lacosamide for fibromyalgia
Posted on June 24, 2008 by crimsoncanary
Data announced today by UCB show its Voltage-gated sodium channel/Collapsin-response mediator protein 2 inhibitor lacosamide to demonstrate efficacy in fibromyalgia syndrome. UCB will decide by the end of 2008 whether to start Phase IIb trials after further analyzing the results
Filed under: Sodium channel | Tagged: lacosamide, na channel, phase II, Phase IIa, UCB, voltage gated | Leave a Comment »
